Foundation Medicine, Inc. Company Profile

20:33 EDT 19th September 2018 | BioPortfolio

Foundation Medicine (NASDAQ: FMI) is a molecular information company focused on fundamentally changing the way patients with cancer are treated. Our proprietary molecular information platform generates actionable genomic information about a patient’s individual cancer, enabling physicians to optimize treatments in clinical practice and enabling biopharmaceutical companies to develop targeted oncology therapies more effectively. The Company’s first clinical product, FoundationOne™, is the first commercially available comprehensive molecular information product designed for use in the routine care of patients with cancer.

Molecular subtypes of cancer

As the molecular drivers of cancer are better understood and more targeted therapies are developed against those drivers, there is an ever-growing need to perform comprehensive molecular analysis of tumors to determine the optimal treatment strategy for each patient. Foundation Medicine is pioneering the development of a comprehensive cancer diagnostic test that represents this critical step toward individualized cancer care by helping physicians recommend treatment options for each patient based on the molecular subtype of their cancer.

A new, cutting edge diagnostic approach

By utilizing next-generation sequencing on small amounts of cancer tissue, relevant genomic information that will help doctors make the most informed treatment recommendations will be captured in one test with greater than 99% sensitivity and specificity for alterations within all relevant cancer genes. Test results will be uniquely reported within the context of publicly available scientific and medical literature and clinical trials, integrating complex genomic research in a coordinated and easily accessible way for physicians to inform treatment recommendations.


One Kendall Square, Suite B3501


Phone: 617-418-2200
Fax: 617-418-2201

News Articles [1012 Associated News Articles listed on BioPortfolio]

Roche buys out rest of Foundation Medicine for $2.4bn

Roche has clearly seen significant potential in Foundation Medicine’s work in genomics to pay $2.4 billion to take complete ownership of the company. The big pharma company had already owned 58% of ...

In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine

Roche this morning agreed to acquire the part of Foundation Medicine it didn’t already own, another big vote of confidence in the broad tumor profiling panels that have struggled to gain traction bu...

Roche Acquires Rest of Foundational Medicine for $2.4B to Enhance Precision Medicine

Roche, today announced it has acquire all of the outstanding shares in Foundation Medicine that is not already owned by Roche and its affiliates for $2.4B, representing $137 per share. Together, the c...

Foundation Medicine Advances Patient Access to Precision Medicine; Pursues Regulatory Approval ...

-- Chugai to Commercialize Foundation Medicine’s Suite of Comprehensive Genomic Profiling (CGP) Services in Japan, Expanding Patient Access to Personalized Cancer Care -- Read mor...

Derfner Foundation funds novel research in regenerative medicine at Kessler Foundation

(Kessler Foundation) Kessler Foundation has received funding from the Derfner Foundation to support applying rehabilitation research to the area of regenerative medicine ('regenerative rehabilitation'...

Roche snaps up rest of Foundation Medicine for $2.4bn

Roche is buying the shares it does not already own in US molecular information company Foundation Medicine (FMI), in a deal valued at $2.4 billion.

Roche to finish purchase of Foundation Medicine

Roche bought a 56% stake in Foundation Medicine in 2015 for $1 billion and is purchasing the remainder of the company later t -More- 

Foundation Medicine Receives New ADLT Status for FoundationOne CDx™ from the Centers for ...

Foundation Medicine, Inc.Media:Lee-Ann Murphy, 617-245-3077pr@foundationmedicine.comorInvestors:Kimberly Brown,

Drugs and Medications [699 Associated Drugs and Medications listed on BioPortfolio]

Esika [Ventura Corporation (San Juan, P.R)]

ēsika 3-in-1 Pro Make Up Foundation SPF 20

Sheer cover mineral foundation [Guthy-Renker LLC]

Sheer Cover Mineral Foundation SPF-15

Cle de peau beaute silky foundation i [SHISEIDO CO., LTD.]

CPB Silky Cream Foundation I

Cle de peau beaute foundation i [SHISEIDO CO., LTD.]

cle de peau BEAUTE Cream Foundation I

Shiseido perfect refining foundation [SHISEIDO AMERICA INC.]

SHISEIDO Perfect Refining Foundation

Clinical Trials [1565 Associated Clinical Trials listed on BioPortfolio]

Olive Oil v Prostate Cancer Foundation Diet for Treatment of Prostate Cancer

This study compared a plant-based, olive oil diet to the diet recommended by the Prostate Cancer Foundation for weight loss and improvement in some laboratory biomarkers.

Concordance Between ctDNA Assay and FoundationOne

Foundation Medicine Inc. (FMI) is interested in studying the concordance of genomic alterations between primary and/or metastatic surgical biopsies, and circulating tumor DNA (ctDNA) withi...

Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary

The goal of the current study is to determine whether Foundation Medicine's next generation sequencing assay, called FoundationOne, will provide information that allows physicians to make ...

The Promotion Plan of Moxibustion on Ulcerate Colitis

To evaluate the efficacy of Moxibustion in the treatment of Ulcerative Colitis, thus the scientific foundation for rational use of Moxibustion in clinical usage, in order to find admission...

Mechanism of Drug-drug Interaction Between Salvianolate Injection and Aspirin

The combination of anti-platelet medicine treatment and Chinese traditional medicine (TCM) promoting blood circulation to removing blood stasis is widely used in treatment for cardiovascul...

Companies [2403 Associated Companies listed on BioPortfolio]

The Medco Foundation

The Medco Foundation was established with the generous support of Medco Health Solutions, Inc. The Foundation focuses on supporting activities aimed at educating and informing the general public about...

Foundation Medicine, Inc. and WuXi PharmaTech

Foundation Medicine (NASDAQ: FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the gen...

The Foundation for Mitochondrial Medicine

The Foundation for Mitochondrial Medicine is a 501(c) (3) non-profit organization dedicated to supporting the development of the most promising research and treatments of the many...

Northwestern Medical Faculty Foundation

Northwestern Medical Faculty Foundation, Inc. (the Foundation) is a premier, multi-specialty physician organization committed to providing high quality care to patients, and to supporting the research...

The Alzheimer’s Drug Discovery Foundation (ADDF) and the Foundation for Mitochondrial Medicine (FMM)

More Information about "Foundation Medicine, Inc." on BioPortfolio

We have published hundreds of Foundation Medicine, Inc. news stories on BioPortfolio along with dozens of Foundation Medicine, Inc. Clinical Trials and PubMed Articles about Foundation Medicine, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Foundation Medicine, Inc. Companies in our database. You can also find out about relevant Foundation Medicine, Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topic

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Corporate Database Quicklinks

Searches Linking to this Company Record